MYOV - Myovant Sciences - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

2.716B

Cash

274.4M

Avg Qtr Burn

-67.47M

Short % of Float

17.90%

Insider Ownership

48.61%

Institutional Own.

56.21%

Qtr Updated

12/31/22

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ORGOVYX (Relugolix) (GnRH receptor antagonist) Details Prostate Cancer	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
MYFEMBREE (Relugolix) (GnRH receptor antagonist) Details Reproductive disease, Endometriosis, Uterine disease	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
MYFEMBREE (Relugolix) (GnRH receptor antagonist) Details Uterine Fibroids	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.